Management of Schizophrenia in Pregnancy

1. Overview and Risk Framework

• Stillbirth and neonatal death
• Post-neonatal mortality (RR 2.76 vs. general population), largely from SIDS (RR 5.23)
• Preterm birth and low birth weight
• Poor antenatal care, higher rates of smoking and substance use

2. General Management Principles

3. Antipsychotic Safety in Pregnancy

First-Generation Antipsychotics (FGAs)

• High-potency agents (haloperidol, trifluoperazine): Preferred historically due to longer safety data
• Low-potency phenothiazines (chlorpromazine): More sedation and anticholinergic effects; less favored
• An early Swedish registry found elevated overall malformation rate; subsequent rigorous studies have been less conclusive when confounders are controlled

Second-Generation Antipsychotics (SGAs)

• A meta-analysis found a doubling of overall malformation risk (OR 2.12; 95% CI 1.25–3.57), with cardiac malformations most common (OR 2.09); however, a large Medicaid registry (n = 1.34 million) did not confirm this after propensity-score adjustment
• Risperidone stands out: associated with mild elevation in any malformation risk (OR 1.26; 95% CI 1.02–1.56) — use with caution
• Olanzapine and quetiapine: Approved for mania; used as alternatives to mood stabilizers in first trimester, but carry metabolic risk
• Clozapine: Reserved for treatment-resistant cases; requires close monitoring

Metabolic Risks of SGAs

• Increased risk of gestational diabetes (attenuated after weight adjustment)
• Insulin resistance and weight gain are prominent with atypical agents, especially olanzapine and clozapine
• Close monitoring of glucose and weight throughout pregnancy is mandatory

Neonatal Effects

• Neonatal Adaptation Syndrome: Irritability, feeding difficulties, tremors — especially with high-dose late-pregnancy exposure
• Neurodevelopmental: At 6 months, only 19% of antipsychotic-exposed infants had normal neuromotor function vs. 50% of unexposed (requires replication and long-term data)
• Perinatal complications: Antipsychotic use associated with preterm birth (OR 1.86) and low birth weight (OR 2.41) vs. untreated comparison

4. Specific Drug Guidance

5. Non-Pharmacological and Monitoring Strategies

• Psychoeducation: Help the patient and family understand illness risks vs. medication risks
• Sleep monitoring: Disruption is an early relapse trigger — monitor proactively in late pregnancy and postpartum
• Social support assessment: Lack of partner support compounds risk of decompensation
• Substance use screening: Higher rates of smoking, alcohol, and illicit drug use must be addressed
• Nutrition counseling: Especially important with olanzapine/clozapine due to metabolic effects
• Neurodevelopmental monitoring of the infant after delivery

6. Postpartum Management

• Schizophrenia patients should continue antipsychotics immediately postpartum — biological risk of relapse is highest in the puerperium due to estrogen withdrawal
• Breastfeeding: Generally avoided with antipsychotics (especially clozapine, which concentrates in breast milk); a risk-benefit discussion with the patient is required
• Enhanced follow-up: Weekly or fortnightly psychiatric contact in the first 3 months postpartum
• Monitor infant for extrapyramidal symptoms and sedation if any breastfeeding occurs

7. Key Contraindications / Agents to Avoid

8. Recent Evidence Update (2025)

Summary

The core principle is: treating schizophrenia in pregnancy is nearly always safer than not treating it. The goal is the lowest effective antipsychotic dose, multidisciplinary care, active monitoring for metabolic and neonatal complications, and intensive postpartum follow-up.